Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily ...

Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted from the same intestinal cells following meal ingestion. GLP-1 is now widely recognised to reduce blood glucose levels ...

The drug is based on a molecule called semaglutide, which mimics the structure of a naturally occurring human hormone called glucagon-like peptide 1 (GLP-1). GLP-1 plays an important role in ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

Relative effects of genetically proxied glucagon‐like peptide‐1 receptor agonism on muscle and fat mass: A Mendelian randomization study. Diabetes, Obesity and Metabolism , 2025; DOI: 10.1111 ...

Amid the soaring use of glucagon-like peptide-1 (GLP-1) drugs for intentional weight loss, a vastly different movement appears to be gaining traction in health care: Many clinicians are pushing for a ...

In this study, the authors first used an AlphaScreen assay to identify a series of tryptophan-based cyclic peptide compounds with FXR-antagonistic activity, specifically those modified with a ...

and promoting glucagon-like peptide-1 (GLP-1) release. This approach holds potential for MASH treatment while maintaining a good safety profile. In this study, the authors first used an ...

Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...